tirzepatide and estradiol together Compounded Injections $100 Men before and after tirzepatide:

The DM control group consisted of patients with T2DM who were prescribed insulin or glucose-lowering drugs but not incretin-based drugs (GLP-1 RAs or DPP-4 inhibitors)

New mechanisms for weight loss are continually being explored, offering new potential drug targets from cannabinoid receptor blockers, nucleotide-binding domain, leucine-richcontaining family, pyrin domaincontaining-3 (NLRP3) inhibitors, free fatty acid receptor 2 (FFA2) inhibitors and gene-editing RNA therapy

While its possible to gain weight back after stopping Semaglutide or other GLP-1 agonists, its not a guaranteed side effect

References 1.Edinoff AN, et al

J., Dai, R., Reisher, E., Korade, Z., & Mirnics, K

This review covers everything you need to know